These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38373481)

  • 1. Effects of androgen deprivation therapy on elderly men with high-risk prostate cancer: PROSARC observational study.
    Legido-Gómez Ó; Rico-Marco S; Lorenzo-Sánchez MV; Navarro-Jiménez S; Tárraga-Honrubia MA; Martínez-Ruiz J; Giménez-Bachs JM; Donate-Moreno MJ; Díaz de Mera-Sánchez-Migallón I; Segura-Martín M; Alcantud-Córcoles R; Abizanda-Soler P; Salinas-Sánchez AS
    Actas Urol Esp (Engl Ed); 2024 May; 48(4):304-310. PubMed ID: 38373481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
    Couderc AL; Villani P; Berbis J; Nouguerède E; Rey D; Rossi D; Lechevallier É; Badinand D; Bastide C; Karsenty G; Boissier R; Amichi K; Muracciole X
    BMC Cancer; 2022 Jan; 22(1):78. PubMed ID: 35042460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
    Couderc AL; Muracciole X; Nouguerede E; Rey D; Schneider S; Champsaur P; Lechevallier E; Lalys L; Villani P
    J Nutr Health Aging; 2020; 24(2):205-209. PubMed ID: 32003412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
    Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
    Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
    Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
    Elife; 2024 Apr; 13():. PubMed ID: 38656229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
    Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
    Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persisting adverse body composition changes 2 years after cessation of androgen deprivation therapy for localised prostate cancer.
    Cheung AS; Tinson AJ; Milevski SV; Hoermann R; Zajac JD; Grossmann M
    Eur J Endocrinol; 2018 Jul; 179(1):21-29. PubMed ID: 29712718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study.
    Cheung AS; Gray H; Schache AG; Hoermann R; Lim Joon D; Zajac JD; Pandy MG; Grossmann M
    J Cachexia Sarcopenia Muscle; 2017 Feb; 8(1):102-112. PubMed ID: 27897410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen deprivation in prostate cancer and the long-term risk of fracture.
    Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
    Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications.
    Shao YH; Moore DF; Shih W; Lin Y; Jang TL; Lu-Yao GL
    BJU Int; 2013 May; 111(5):745-52. PubMed ID: 23331464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
    Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
    Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderators of resistance-based exercise programs' effect on sarcopenia-related measures in men with prostate cancer previously or currently undergoing androgen deprivation therapy: An individual patient data meta-analysis.
    Lopez P; Newton RU; Taaffe DR; Winters-Stone K; Galvão DA; Buffart LM
    J Geriatr Oncol; 2023 Jun; 14(5):101535. PubMed ID: 37229882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy in prostate cancer and risk of developing renal calculi: Results of a case-control study.
    Díaz Convalía EJ; Cano-García MDC; Miján-Ortiz JL; Arrabal-Martín M; Arrabal-Polo MÁ; Cózar-Olmo JM
    Med Clin (Barc); 2017 Jun; 148(11):495-497. PubMed ID: 28256207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
    BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study.
    Ng HS; Koczwara B; Roder D; Vitry A
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.
    Krupski TL; Smith MR; Lee WC; Pashos CL; Brandman J; Wang Q; Botteman M; Litwin MS
    Cancer; 2004 Aug; 101(3):541-9. PubMed ID: 15274067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.